TRIKAFTA (COPACKAGED) Drug Patent Profile

When do Trikafta (copackaged) patents expire, and what generic alternatives are available?

Trikafta (copackaged) is a drug marketed by Vertex Pharms Inc and is included in two NDAs. There are thirty-five patents protecting this drug.

The generic ingredient in TRIKAFTA (COPACKAGED) is elexacaftor, ivacaftor, tezacaftor; ivacaftor. One supplier is listed for this compound. Additional details are available on the elexacaftor, ivacaftor, tezacaftor; ivacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Trikafta (copackaged)

Trikafta (copackaged) was eligible for patent challenges on October 21, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 8, 2037. This may change due to patent challenges or generic licensing.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRIKAFTA (COPACKAGED)

US Patents:	35
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIKAFTA (COPACKAGED)

US Patents and Regulatory Information for TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) is protected by one hundred and twenty-nine US patents and ten FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,453,655.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULE;ORAL	217660-001	Apr 26, 2023		RX	Yes	No	8,883,206		Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-001	Oct 21, 2019		RX	Yes	Yes	12,458,635		Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULE;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes	8,324,242
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-001	Oct 21, 2019		RX	Yes	Yes	11,564,916

International Patents for TRIKAFTA (COPACKAGED)

When does loss-of-exclusivity occur for TRIKAFTA (COPACKAGED)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hungary

Israel

Japan

Jordan

Lithuania

Mexico

Moldova, Republic of

Morocco

New Zealand

Peru

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIKAFTA (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2007235260
Brazil	PI0710965
Canada	2648719
Canada	2869945

Supplementary Protection Certificates for TRIKAFTA (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1773816	CA 2015 00038	Denmark		PRODUCT NAME: IVACAFTOR, N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLIN-3-CARBOXAMID ELLER ET FARMACEUTISK ACCEPTABLET SALT DERAF; REG. NO/DATE: EU/1/12/782/001-002 20120723
2826776	2190015-4	Sweden		PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2- METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/18/1306, 2018-11-06; DEN 19 JUNI 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 1790034-1 1490061-7 1790019-2 2090047-8 2390009-5 2390012-9 2090033-8 1790016-8 2190015-4 1990020-8 1090038-9 1190029-7
1773816	92761	Luxembourg		PRODUCT NAME: N-(5-HYDROXY-2,4-DIERT-BUTYL-PHENYL)-4OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER: EU/1/12/782/001-002
1773816	122015000050	Germany		PRODUCT NAME: N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-CHINOLIN-3-CARBONSAEUREAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120723

TRIKAFTA (copackaged) Investment Scenario and Fundamentals Analysis: exclusivity runway, patent estate strength, FDA status, and generic/biosimilar entry risk

Last updated: July 25, 2026

TRIKAFTA (copackaged) is Vertex’s CFTR-targeted, triple-combination therapy (elexacaftor/tezacaftor/ivacaftor) for cystic fibrosis. The investment case hinges on (1) remaining U.S./EU exclusivity and patent tail risk, (2) whether next-generation CFTR franchises or payer dynamics erode share, and (3) the timing and probability of generic entry under Hatch-Waxman. For investors, the near-to-mid term profile depends more on regulatory scope expansion and access than on pipeline substitution, because the patent moat around the copackaged combination and dosing regimens is the core barrier to oral small-molecule competition.

---

What patents protect TRIKAFTA (copackaged) and how strong is the patent estate?

Short answer: The TRIKAFTA moat is built on composition-of-matter and formulation/combination claims covering elexacaftor/tezacaftor/ivacaftor as a therapeutic regimen, plus additional patents targeting specific dosage forms and dosing schedules. For investment risk, the key question is not whether there are patents, but whether Vertex has unexpired claims in the U.S. that cover the marketed copackaged regimen and whether challengers have a credible design-around route.

Composition and combination coverage: why “copackaged” matters

TRIKAFTA is marketed as a copackaged regimen, typically requiring administration of two distinct tablets (one containing elexacaftor/tezacaftor/ivacaftor and one containing ivacaftor alone depending on patient weight/age). Copackaging is a patent- and enforcement-relevant construct because it can support claims that require a specific combination schema rather than a single unitary formulation.

Investment implication: even if generic manufacturers can match each active ingredient’s potency, Hatch-Waxman entry risk remains lower when claims cover (a) the combination use, (b) the regimen sequence, and (c) the specific copackaged dosing scheme.

Method-of-treatment and regimen claims: what challengers try to avoid

Generic applicants often attack by arguing noninfringement or invalidity of:

• method-of-use claims (patient selection, CFTR genotype-based indications, dosing instructions)
• regimen-specific claims (copackaged schedule and patient-administration instructions)
• formulation claims tied to release, stability, or excipient systems

Investment implication: the presence of regimen and dosing patents extends the effective exclusivity beyond the earliest composition expiry if the Orange Book lists relevant patents tied to the approved labeling and regimen.

How the patent estate translates into business protection

For an investment-grade view, the relevant metric is the number of listed, unexpired U.S. patents per drug product and whether they are still asserted in litigation when challengers file.

Practical framework used by investors:

1. Orange Book listing density for TRIKAFTA’s drug product and strength.
2. Litigation posture at the time of the first Paragraph IV certifications.
3. Remaining years on the latest “blocking” patent (not the earliest).
4. Likelihood of design-around based on claim scope and regimen dependence.

Outcome-driven conclusion: TRIKAFTA’s exclusivity strength is strongest when Vertex retains a late-expiring U.S. patent that is both (a) Orange Book-listed for the marketed regimen and (b) difficult to design around because claims require the copackaged combination schema.

---

When does TRIKAFTA (copackaged) lose exclusivity in the U.S. and what are the key expiration dates?

Short answer: The exclusivity calendar for a triple-combination CFTR modulator is driven by a mix of patent expirations and marketing exclusivities (including possible pediatric-related protections depending on FDA history). For investors, the decisive factor is the latest U.S. blocking patent date tied to the Orange Book.

U.S. exclusivity runway: what to anchor to

• Latest expiring Orange Book “blocking” patent (for the TRIKAFTA drug product and strengths)
• Possible later-dated exclusivities triggered by supplemental approvals (label expansions)
• Pediatric exclusivity if applicable based on FDA’s exclusivity coding and timing

Europe and other jurisdictions: how the runway changes

Europe’s protection is usually anchored to:

• European patent family expirations
• Supplementary Protection Certificates (SPCs) where applicable
• national regulatory exclusivity rules

Investment implication: If U.S. protection weakens earlier than key EU markets, it affects geographic revenue risk. Conversely, longer EU patent life can stabilize international cash flows even if U.S. exclusivity tightens.

(No exact date table is provided here because a complete and accurate set of TRIKAFTA Orange Book and FDA exclusivity dates requires product-specific listing retrieval, and the prompt provides no FDA/Orange Book identifiers.)

---

What is the Orange Book status of TRIKAFTA (copackaged) and which patents are listed for Paragraph IV challenges?

Short answer: Orange Book status determines whether a generic can file a Paragraph IV certification and automatically triggers a 30-month stay if litigation is pursued. For TRIKAFTA, the risk is not generic entry alone, but whether challengers can certify noninfringement or invalidity against the specific listed patents that cover the approved copackaged regimen.

What investors monitor on Orange Book listings

• Number of listed patents by drug product (strength/packaging)
• Whether patents are active/in-force
• Patent types (composition, formulation, method-of-use)
• Injunction and litigation history tied to those listed patents

Practical investor read-through

If Orange Book lists multiple patents with staggered expirations:

• challengers typically target the most vulnerable (earliest-expiring) listed patents first
• Vertex’s enforcement tends to focus on “blocking” patents that cover the commercial product and dosing regimen

Investment implication: the probability-weighted outcome is a function of which patents are easiest to attack and which are “blocking” for regulatory approval.

(Orange Book dataset is not reproduced here because the prompt does not include Orange Book drug product identifiers and the response requires exact listings to be complete and accurate.)

---

Which companies are challenging TRIKAFTA (copackaged) with Paragraph IV and what settlements changed the economics?

Short answer: Paragraph IV challenges are the inflection point where the market moves from “patent tail” to “probabilistic generic entry.” The key is identifying:

• filer identity
• the patent set challenged
• court outcomes or settlement entry dates

(No exact challengers, case numbers, or settlement terms are included because that requires verified litigation docket and settlement agreement details. The prompt does not provide such data.)

What settlements typically do to the investment case

Settlement agreements often:

• fix a generic launch date
• include agreed carve-outs for certain strengths or patient populations
• impose licensing terms or non-cash consideration

Investment implication: even where generic entry is delayed, settlements can accelerate market expectation of eventual erosion, affecting valuation multiples.

---

What patent litigation affects TRIKAFTA (copackaged) and how should investors map case outcomes to revenue risk?

Short answer: Litigation changes revenue risk by altering the probability distribution of generic entry. Investors typically map outcomes by:

• validity rulings (invalidity probability)
• infringement findings (noninfringement defenses)
• appeal timelines and stay dynamics
• injunction scope (what generic can or cannot launch)

How to translate litigation timelines into commercial scenarios

A structured scenario approach:

• Base case: litigation continues through expected appeal windows; generic entry occurs at the first feasible regulatory moment after blocking patent expiry.
• Adverse case: early invalidity/noninfringement rulings remove blockers sooner than calendar-based expectations.
• Favorable case: Vertex wins broadly or settlements push entry beyond the next patent tranche.

Investment implication: the market usually prices the median scenario; valuation downside comes from tail outcomes that shorten the effective exclusivity period.

(Litigation specifics are omitted for the same reason as above: complete accuracy requires docket- and settlement-level sourcing.)

---

How does TRIKAFTA (copackaged) compare with KALYDECO, ORKAMBI, SYMDEKO, and other CFTR modulators for competitive and pricing risk?

Short answer: TRIKAFTA is a higher-efficacy triple combination that can expand eligible patient populations relative to older modulators that were genotype-limited. Competitive risk now centers on payer access, formulary dynamics, and whether other next-generation CFTR modulators change the competitive set.

Competitive set: where TRIKAFTA sits

• Older CFTR modulators (e.g., single-agent ivacaftor or two-drug combinations) typically cover narrower genotype ranges or have lower clinical effect.
• TRIKAFTA’s commercial strength historically reflected both clinical outcomes and the breadth of treated genotypes.

Investment implication: as long as TRIKAFTA’s labeled eligibility remains broad and real-world outcomes stay strong, payer pushback tends to be managed through contracting rather than rapid displacement.

Pricing and access as “soft exclusivity”

Even with strong patents:

• payer utilization management and rebates can pressure net price
• health technology assessment (HTA) processes can cap budgets in some geographies

Investment implication: patent expiry is not the only risk driver. Net revenue erosion can occur from access levers before generics arrive.

---

What generic entry risks exist for TRIKAFTA (copackaged) and what would generic launch require?

Short answer: Generic entry risk depends on whether challengers can obtain regulatory approval without infringing composition/formulation/regimen patents and whether they can manufacture a copackaged regimen that matches approved dosing and labeling. For an oral small molecule triple regimen, the main barrier is legal rather than purely technical.

Required components for launch

• Regulatory approval pathway (Hatch-Waxman for small molecules)
• FDA approval of bioequivalence and labeling consistent with generic requirements
• Patent certification compliance and resolution of Paragraph IV disputes

Technical barriers investors should still consider

Even if legal blockers fall:

• formulation differences can affect bioequivalence
• patient regimen requirements can limit substitutability if labeling differs

Investment implication: a generic that only replicates one active ingredient is not a true substitute. A true TRIKAFTA regimen substitute requires the triple-combination schema consistent with marketing authorization.

---

What formulations are protected by TRIKAFTA (copackaged) patents, including dosage forms and stability claims?

Short answer: The patent estate likely includes protection for oral dosage forms and formulation aspects tied to the marketed tablet strengths and the copackaged dosing scheme.

Formulation claim categories investors track

• tablet composition and coating systems
• stability and polymorph-related protections
• excipient systems enabling absorption characteristics
• manufacturing process claims that restrict how the product is made

Investment implication: formulation-process patents can delay “workaround” substitutes even when composition claims face challenges.

---

What method-of-use or dosing regimen patents protect TRIKAFTA (copackaged)?

Short answer: Regimen patents often protect how patients are dosed, when therapy is used, and how copackaged administration is structured.

Method-of-use vs label-driven infringement

• If claims are tied to therapeutic use language in the FDA labeling, generic applicants must align with that labeling.
• If claims are tied to specific dosing instructions, differences in labeling can be used as a design-around tactic, but only if the FDA allows the labeling carve-out.

Investment implication: the strength of dosing/regimen claims increases the chance that “generic entry” is delayed or limited to partial-market segments.

---

What regulatory milestones and FDA status drive TRIKAFTA (copackaged) lifecycle value?

Short answer: Value is driven by supplemental approvals that expand patient eligibility and by labeling precision that reduces substitution risk.

What to monitor in FDA history

• indication expansions (age and genotype expansion)
• dosing regimen updates for different patient groups
• pediatric dosing schedules and age-based formulations
• postmarketing commitments that may influence manufacturing continuity

Investment implication: each meaningful label expansion can extend the commercial product’s protected addressable market even if patents near expiry.

(FDA milestones are not enumerated here because an accurate, product-specific milestone list requires retrieval of FDA approval histories for each supplement, which is not included in the prompt.)

---

How many patents cover TRIKAFTA (copackaged) across major jurisdictions and what is the geographic coverage risk?

Short answer: TRIKAFTA is protected by a patent family distributed across major jurisdictions (US, EP, and likely additional national filings). Geographic risk is typically the earliest patent expiry in any revenue-relevant market and the presence or absence of SPCs.

Geographic coverage drivers

• where the earliest priority leads to earliest granted expiry
• presence of SPC extensions
• strength of enforcement and litigation track record in that jurisdiction

Investment implication: investors model “global cash flow thinning” by market. Strong US and EU protection can offset faster weakness in smaller markets, but uneven expiry can create uneven revenue erosion.

(Patent counts by jurisdiction require verified patent family analytics, not provided in the prompt.)

---

What commercial metrics matter for investing in TRIKAFTA (copackaged) fundamentals?

Short answer: The fundamentals are net revenue growth/decline, margin durability (manufacturing and access costs), patient persistence, and payer contracting outcomes. Patent and regulatory risk translate into revenue visibility and discount rates.

Investment-grade KPIs to anchor

• U.S. and international net sales trends (quarterly)
• mix shifts: age and genotype distribution
• pharmacy channel and payer coverage expansion
• headcount and R&D spend relative to sales base
• manufacturing capacity stability and supply assurance

Revenue sensitivity mapping

• Patent risk changes the tail probability of generic erosion.
• Access risk changes net price now, even with patents intact.
• Competition risk changes utilization and payer willingness to exclude competitors from formularies.

Investment implication: the highest near-term sensitivity is usually access and real-world persistence, while patent litigation drives longer-horizon valuation.

(No numeric commercial metrics are included because the prompt does not provide TRIKAFTA revenue series, segment reporting, or Vertex financials.)

---

How does TRIKAFTA (copackaged) compare with emerging CFTR strategies and pipeline substitution risk?

Short answer: Substitution risk depends on whether next-generation CFTR modulators or non-CFTR approaches change the standard of care in a clinically meaningful way or win payer adoption.

Substitution vectors investors test

• improved dosing convenience or tolerability
• broader genotype coverage
• better long-term clinical outcomes
• head-to-head or real-world adherence advantages

Investment implication: unless an alternative is labeled for the same patient populations with superior outcomes and payer preference, TRIKAFTA remains the default CFTR modulator benchmark.

---

Key Takeaways

• TRIKAFTA’s investment case is dominated by its ability to retain market exclusivity through the continued enforceability of Orange Book-listed patents covering the copackaged triple regimen.
• The decisive risk is not generic entry in the abstract but whether challengers can invalidate or design around “blocking” U.S. patents tied to the marketed regimen and dosing instructions.
• Short-to-mid term fundamentals are more sensitive to access, payer contracting, and persistence than to patent expiries.
• Litigation outcomes and settlement terms determine whether the market should price an earlier-than-calendar generic scenario.

---

FAQs

1. What patent types most often block generic TRIKAFTA (copackaged) approval?
2. How does copackaging affect infringement and generic design-around strategies for TRIKAFTA?
3. What happens to TRIKAFTA exclusivity when Vertex expands pediatric or genotype coverage through FDA supplements?
4. How do Paragraph IV certifications influence TRIKAFTA’s generic entry probability and timing?
5. Which market is most exposed first if TRIKAFTA patent coverage weakens: the U.S. or major EU countries?

---

References

(No references are provided because the prompt does not include any source material, and producing an accurate patent, Orange Book, and litigation map requires product-specific FDA and docket verification that is not present in the input.)